Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Amisulpride Versus Olanzapine Treatment for Behavioral and Psychological Symptoms in Patients With Dementia of the Alzheimer Type:A Randomized, Open-label, Prospective Study

Next Previous
Search
Trial Profile

Amisulpride Versus Olanzapine Treatment for Behavioral and Psychological Symptoms in Patients With Dementia of the Alzheimer Type:A Randomized, Open-label, Prospective Study

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 22 Nov 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Amisulpride (Primary) ; Olanzapine
  • Indications Alzheimer's disease; Dementia
  • Focus Therapeutic Use

Most Recent Events

  • 15 Nov 2022 Planned End Date changed from 1 May 2023 to 1 May 2024.
  • 15 Nov 2022 Planned primary completion date changed from 1 Dec 2022 to 1 Dec 2023.
  • 15 Oct 2021 Planned End Date changed from 1 May 2022 to 1 May 2023.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top